opium alkaloids
Botanicalexperimental
Laudanum is a tincture of opium containing approximately 10% powdered opium by weight. Laudanum is prepared by dissolving extracts from the opium poppy in alcohol (ethanol). — Wikipedia
Clinical trial activity
14 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
4
Phase 4
6
Earliest trial started Jan 1, 2007 (NCT01723722)
Timeline
Indications
Approved for
Studied for
- Diarrhea · Phase 3
- Enteritis · Phase 3
- Hysterectomy · Phase 4
- Intestinal Diseases · Phase 3
- Neonatal Abstinence Syndrome · Phase 4
- Neoplasms · Phase 3
- Nephrolithiasis · Phase 4
- Opioid-Related Disorders · Phase 3
- Pain · Phase 4
- Postoperative Pain · Phase 4
- Short Bowel Syndrome · Phase 3
- Urinary Bladder, Overactive · Phase 4
- Vagina · Phase 4
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLaudanum ↗
- NCATS37M3MZ001L ↗
- ChEMBLCHEMBL2107915 ↗
- ChEMBLCHEMBL2107914 ↗
Also known as
- camph opium
- diluted opium powder
- opium
- opium
- opium
- opium
- opium alkaloids
- opium alkaloids hydrochlorides
- opium camph co
- opium, powdered
- opium tincture
- opium tincture
- opium tincture (laudanum)
- papaver somniferum exudate
- papaver somniferum resin
- powdered opium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05690321 | Phase 2 | Nov 17, 2022 | Aalborg University, Aarhus University |
| NCT05702190 | N/A | Mar 9, 2021 | Aalborg University |
| NCT03657407 | Phase 4 | Jun 1, 2016 | Mercy Medical Center, University of Maryland |
| NCT02865395 | Phase 4 | Mar 1, 2016 | George Washington University |
| NCT02291042 | N/A | Oct 1, 2015 | Southern New Hampshire Medical Center |
| NCT02502175 | Phase 3 | Sep 1, 2015 | Isfahan University, University of British Columbia |
| NCT02246816 | Phase 3 | Feb 1, 2015 | Marathon Pharmaceuticals |
| NCT02242656 | Phase 3 | Dec 1, 2014 | Marathon Pharmaceuticals |
| NCT03332056 | Phase 4 | Aug 31, 2013 | University of Washington |
| NCT01150474 | Phase 4 | Jan 1, 2011 | Mayo Clinic |
| NCT01271855 | Phase 4 | May 1, 2009 | Loyola University |
| NCT00863928 | N/A | Mar 17, 2009 | Virginia Mason Medical Center |
| NCT00444093 | Phase 3 | Sep 1, 2007 | Maros Arzneimittel GmbH, Philipps University of Marburg |
| NCT01723722 | Phase 4 | Jan 1, 2007 | Eastern Maine Medical Center |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aalborg University | Academic/Hospital | 2 | 2 | 2 | 2021 |
| Marathon Pharmaceuticals | For profit | 2 | 2 | 1 | 2014 |
| Aarhus University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Eastern Maine Medical Center | Academic/Hospital | 1 | 1 | 1 | 2007 |
| George Washington University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Isfahan University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Loyola University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Maros Arzneimittel GmbH | For profit | 1 | 0 | 1 | 2007 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Mercy Medical Center | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Philipps University of Marburg | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Southern New Hampshire Medical Center | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of British Columbia | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Virginia Mason Medical Center | Academic/Hospital | 1 | 1 | 1 | 2009 |
16 organizations
Page 1 / 1